Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and is expanding its incretin franchise with promising new drugs like retatrutide and Foundeo. In contrast, Merck's Q2 revenue grew only 5%, with KEYTRUDA's growth plateauing and the company facing a significant patent cliff. Merck is focusing on diversifying its portfolio with new launches like Lipvendra but faces uncertainty in timing and growth durability. Lilly's robust pipeline and raised guidance position it as a more durable growth story through 2030, while Merck may appeal more to value investors due to its lower valuation and dividend yield.
Following the contrasting growth stories of Eli Lilly and Merck, Eli Lilly's stock on Pluang is trading at USD 1,155.65 with a 1.57% gain as of Sep 15, 2026 19:16 WIB, reflecting strong investor interest. Merck's shares are priced at USD 143.80, down slightly by 0.13% at the same time, highlighting a more cautious market stance. Eli Lilly's market cap stands at $1.01 trillion, significantly larger than Merck's $357.37 billion, underscoring its dominant position in the health sector.
The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benc...
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...
August's inflation report showed headline inflation steady and core inflation falling to its lowest in over five years, signaling easing price pressures. Despite this positive data, the Federal Reserve is still expected to raise interest rates to con...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Eli Lilly has finalized its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health, including treatment-resistant depression. This acquisition aims to introduce inno...
